IP Library Granted Patent US 11,254,792
Granted Patent B2
US 11,254,792 · App. 16/066,746 · Granted Feb 22, 2022

Method for deacetylation of biopolymers

Inventors: Johan Olsson (Bromma, SE); Craig Steven Harris (Biot, FR)
Assignee: GALDERMA HOLDING SA
C08J3/075A61K8/042A61K8/73A61K8/735A61K9/0019A61Q19/00C07C209/62C07C213/00C07C269/06C07F7/083C08B37/0063C08B37/0069C08B37/0072C08J3/24C08J7/14C08K5/09C08L5/00C08L5/08C07C2603/18C08J2305/00C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,254,792
App. No.
16/066,746
Granted
Feb 22, 2022
Kind
B2
Abstract

A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH 2 OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.

Claims (19)

1. A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, the method comprising:

(a) obtaining a solution comprising an at least partially deacetylated glycosaminoglycan with a degree of acetylation between 50% and 99% and a second glycosaminoglycan, wherein the second glycosaminoglycan is different from the at least partially deacetylated glycosaminoglycan;

(b) activating carboxyl groups on the at least partially deacetylated glycosaminoglycan and/or the second glycosaminoglycan with a coupling agent, to form activated glycosaminoglycans;

(c) crosslinking the activated glycosaminoglycans via two different crosslinkers solely with amide bonds to provide crosslinked glycosaminoglycans; and

(d) acylating residual amine groups of the crosslinked glycosaminoglycans obtained in (c) to form acylated crosslinked glycosaminoglycans; and

(e) subjecting the crosslinked glycosaminoglycans provided in (c) or (d) to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking in (c),

wherein the first and second glycosaminoglycans are not the two different crosslinkers, and wherein the two different crosslinkers are carbohydrate-based crosslinkers.

2. The method according to claim 1 , wherein the second glycosaminoglycan is at least partially deacetylated.

3. The method according to claim 1 , wherein the second glycosaminoglycan is not deacetylated.

4. The method according to claim 1 , wherein the glycosaminoglycans are selected from hyaluronic acid, chondroitin, chondroitin sulphate, heparin sulphate, heparosan, heparin, dermatan sulphate, and keratin sulphate.

5. The method according to claim 1 , wherein the at least partially deacetylated glycosaminoglycan and/or the second glycosaminoglycan is hyaluronic acid.

6. The method according to claim 1 , wherein the at least partially deacetylated glycosaminoglycan and the second glycosaminoglycan are hyaluronic acids.

7. The method according to claim 1 , wherein (b) and (c) occur simultaneously.

8. The method according to claim 1 , wherein (b) occurs prior to (c).

9. The method according to claim 1 , wherein the hydrogel product comprises a portion of glycosaminoglycans which are not crosslinked.

10. The method according to claim 9 , wherein the crosslinked glycosaminoglycan molecules comprise at least 80% by weight of the hydrogel product.

11. The method according to claim 1 , wherein the at least partially deacetylated glycosaminoglycan has a degree of acetylation between 93% and 99%.

12. The method according to claim 1 , wherein the second glycosaminoglycan obtained in a) is not altered or modified by addition or removal of functional groups.

13. The method according to claim 1 , wherein at least one of the two different crosslinkers is diaminotrehalose.

Assignments (5)
CHANGE OF ADDRESS Recorded Jun 27, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 061113/0710 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEES ADDRESS PREVIOUSLY RECORDED AT REEL: 057652 FRAME: 0859. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 13, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 058495/0582 →
CHANGE OF NAME Recorded Sep 29, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057631/0589 →
AMENDMENT TO ASSET TRANSFER AGREEMENT Recorded Sep 29, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057652/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2019
From: OLSSON, JOHAN; HARRIS, CRAIG STEVEN
To: GALDERMA S.A
Reel/Frame 048659/0775 →
Cited By (2)
US 12,667,534 US 12,673,131